Clinical risk management in Dutch community pharmacies - The case of drug-drug interactions

被引:37
作者
Buurma, Henk
De Smet, Peter A. G. M.
Egberts, Antoine C. G.
机构
[1] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands
[3] Sci Inst Dutch Pharmacists, WINAp, The Hague, Netherlands
[4] Univ Nijmegen Med Ctr St Radboud, Dept Clin Pharm, Nijmegen, Netherlands
关键词
D O I
10.2165/00002018-200629080-00009
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The prevention of drug-drug interactions requires a systematic approach for which the concept of clinical risk management can be used. The objective of our study was to measure the frequency, nature and management of drug-drug interaction alerts as these occur in daily practice of Dutch community pharmacies. Methods: In total, 63 Dutch pharmacies collected all drug-drug interaction alerts during 153 research days (on average 2.4 days/pharmacy), as well as variables related to these alerts, such as involved medicines, first time or recurrent drug-drug interaction, same or different prescribers, patient data (age, sex) and information about the management of drug-drug interactions by the pharmacy. The latter was discriminated into internal procedures only and external action, such as communication with the patient, the prescriber or the anticoagulation clinic and prescription modification. All drug-drug interactions were classified into categories of clinical relevance (A-F) and available evidence (0-4). Results: A total of 43 129 prescription-only medicines were dispensed during the study period. On average, 16.8 interaction alerts per day per pharmacy were collected. Approximately 6% of all prescriptions generated a drug-drug interaction alert. Of all alerts (n = 2572), 31.1 % occurred for the first time and with 21 % two different prescribers were involved. The 20 most frequently occurring drug-drug interaction alerts accounted for approximately 76% of all alerts. Cardiovascular drugs, NSAIDs, oral contraceptives and antibacterials were most frequently involved. External action was taken in response to 27.3% of the alerts, meaning either a modification of one of the concerned prescriptions (n = 65; 9.3%), communication with the prescriber or anticoagulation clinic (n = 90; 12.8%) or communication with the patient or a relative (n = 547; 77.9%). Where there was no external action (n = 1860; 72.3%), pharmacists concluded in about two-thirds of cases that the drug-drug interaction had been managed in the past. Other reasons not to intervene externally were for instance: incorrect alert; acceptable drug-drug interaction; or outcome of the interaction considered irrelevant. Adjusted for several variables, a first alert was found to be a main determinant for external action. After stratifying for first alerts no other significant determinants were found. Conclusions: A high frequency of drug-drug interaction alerts was found. Most concerned recurrent alerts, which were the main reason not to act externally. Concerning the assessment phase in the risk-management process, drug-drug interactions with no or low evidence/relevance should be reconsidered. Concerning the management of drug-drug interactions in pharmacies, the opportunity to actively suppress alerts for a certain period of time should be studied in more detail. There are indicators that the management of patient-orientated advice could be improved and a greater degree of consistency developed for the management of first and recurrent interaction alerts.
引用
收藏
页码:723 / 732
页数:10
相关论文
共 36 条
  • [1] Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582
  • [2] [Anonymous], 2000, Cochrane Database of Systematic Reviews, DOI [DOI 10.1002/14651858.CD000336, 10.1002/14651858.CD000336]
  • [3] Primary prevention of allergy and asthma is possible
    Becker, AB
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 28 (01) : 5 - 16
  • [4] Drug interactions in primary care: Impact of a new algorithm on risk determination
    Bergk, V
    Gasse, C
    Rothenbacher, D
    Loew, M
    Brenner, H
    Haefeli, WE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) : 85 - 96
  • [5] Exposure to potential drug interactions in primary health care
    Bjerrum, L
    Andersen, M
    Petersen, G
    Kragstrup, J
    [J]. SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2003, 21 (03) : 153 - 158
  • [6] Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors
    Bouvy, ML
    Heerdink, ER
    Hoes, AW
    Leufkens, HGM
    [J]. DRUG SAFETY, 2003, 26 (13) : 983 - 989
  • [7] Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention
    Bouvy, ML
    Buurma, H
    Egberts, TCG
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2002, 27 (02) : 107 - 110
  • [8] Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital
    Boyko, WL
    Yurkowski, PJ
    Ivey, MF
    Armitstead, JA
    Roberts, BL
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (14) : 1591 - 1595
  • [9] Evaluation of the clinical value of pharmacists' modifications of prescription errors
    Buurma, H
    De Smet, PAGM
    Leufkens, HGM
    Egberts, ACG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (05) : 503 - 511
  • [10] Nature, frequency and determinants of prescription modifications in Dutch community pharmacies
    Buurma, H
    de Smet, PAGM
    van den Hoff, OP
    Egberts, ACG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (01) : 85 - 91